Suwen Qi1, Depeng Xu1, Qiaoliang Li2, Ni Xie3, Jun Xia3, Qin Huo3, Pu Li4, Qiwen Chen1, Si Huang1. 1. Department of Biomedical Engineering, School of Medicine, Shenzhen University, Shenzhen 518060, China. 2. Department of Biomedical Engineering, School of Medicine, Shenzhen University, Shenzhen 518060, China. Electronic address: lql@szu.edu.cn. 3. Shenzhen Second Hospital, The First Affiliated hospital of Shenzhen University, Shenzhen 518060, China. 4. Department of Laboratory Medicine, The Second Hospital Affiliated to Chongqing Medical University, 410006 Chongqing, China.
Abstract
OBJECTIVE: A key step in managing non-alcoholic fatty liver disease (NAFLD) is to differentiate nonalcoholic steatohepatitis (NASH) from simple steatosis (SS). METHOD: Serum samples were collected from three groups: NASH patients (N=21), SS patients (N=38) and healthy controls (N=31). High performance liquid chromatography-mass spectrometry (HPLC-MS) was used to analyse the metabolic profile of the serum samples. The acquired data were processed by multivariate principal component analysis (PCA) and orthogonal partial least-squares-discriminant analysis (OPLS-DA) to identify novel metabolites. The potential biomarkers were quantitatively determined and their diagnostic power was further validated. RESULTS: A total of 56 metabolites were capable of distinguishing NASH from SS samples based on the OPLS-DA model. Pyroglutamate was found to be the most promising factor in distinguishing the NASH from SS groups. With an optimal cut-off value of 4.82mmol/L, the sensitivity and specificity of the diagnosis of NASH were 72% and 85%, respectively. The area under the receiver operating characteristic (AUROC) of the pyroglutamate levels of NASH versus SS patients was more than those of tumor necrosis factor-α, adiponectin and interleukin-8. CONCLUSION: These data suggest that pyroglutamate may be a new and useful biomarker for the diagnosis of NASH.
OBJECTIVE: A key step in managing non-alcoholic fatty liver disease (NAFLD) is to differentiate nonalcoholic steatohepatitis (NASH) from simple steatosis (SS). METHOD: Serum samples were collected from three groups: NASH patients (N=21), SS patients (N=38) and healthy controls (N=31). High performance liquid chromatography-mass spectrometry (HPLC-MS) was used to analyse the metabolic profile of the serum samples. The acquired data were processed by multivariate principal component analysis (PCA) and orthogonal partial least-squares-discriminant analysis (OPLS-DA) to identify novel metabolites. The potential biomarkers were quantitatively determined and their diagnostic power was further validated. RESULTS: A total of 56 metabolites were capable of distinguishing NASH from SS samples based on the OPLS-DA model. Pyroglutamate was found to be the most promising factor in distinguishing the NASH from SS groups. With an optimal cut-off value of 4.82mmol/L, the sensitivity and specificity of the diagnosis of NASH were 72% and 85%, respectively. The area under the receiver operating characteristic (AUROC) of the pyroglutamate levels of NASH versus SS patients was more than those of tumor necrosis factor-α, adiponectin and interleukin-8. CONCLUSION: These data suggest that pyroglutamate may be a new and useful biomarker for the diagnosis of NASH.
Authors: Pengfei Guo; Tristan Furnary; Vasilis Vasiliou; Qi Yan; Kate Nyhan; Dean P Jones; Caroline H Johnson; Zeyan Liew Journal: Environ Int Date: 2022-02-26 Impact factor: 9.621